WO2006092230A3 - Proteinbindende camptothecin-peptid-derivate und diese enthaltende arzneimittel - Google Patents

Proteinbindende camptothecin-peptid-derivate und diese enthaltende arzneimittel Download PDF

Info

Publication number
WO2006092230A3
WO2006092230A3 PCT/EP2006/001624 EP2006001624W WO2006092230A3 WO 2006092230 A3 WO2006092230 A3 WO 2006092230A3 EP 2006001624 W EP2006001624 W EP 2006001624W WO 2006092230 A3 WO2006092230 A3 WO 2006092230A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
binding
peptide derivatives
medicaments
same
Prior art date
Application number
PCT/EP2006/001624
Other languages
English (en)
French (fr)
Other versions
WO2006092230A2 (de
Inventor
Felix Kratz
Andre Warnecke
Bjoern Schmid
Original Assignee
Ktb Tumorforschungs Gmbh
Felix Kratz
Andre Warnecke
Bjoern Schmid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ktb Tumorforschungs Gmbh, Felix Kratz, Andre Warnecke, Bjoern Schmid filed Critical Ktb Tumorforschungs Gmbh
Publication of WO2006092230A2 publication Critical patent/WO2006092230A2/de
Publication of WO2006092230A3 publication Critical patent/WO2006092230A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die Erfindung betrifft Camptothecin-Peptid-Derivate, die eine proteinbindende Gruppe enthalten und enzymatisch im Körper unter Freisetzung des Wirkstoffs oder eines niedermolekularen Wirkstoff-Derivates spaltbar sind.
PCT/EP2006/001624 2005-02-28 2006-02-22 Proteinbindende camptothecin-peptid-derivate und diese enthaltende arzneimittel WO2006092230A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005009099 2005-02-28
DE102005009099A DE102005009099A1 (de) 2005-02-28 2005-02-28 Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
WO2006092230A2 WO2006092230A2 (de) 2006-09-08
WO2006092230A3 true WO2006092230A3 (de) 2006-11-23

Family

ID=36606087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/001624 WO2006092230A2 (de) 2005-02-28 2006-02-22 Proteinbindende camptothecin-peptid-derivate und diese enthaltende arzneimittel

Country Status (2)

Country Link
DE (1) DE102005009099A1 (de)
WO (1) WO2006092230A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006035083A1 (de) * 2006-07-28 2008-01-31 medac Gesellschaft für klinische Spezialgeräte mbH Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
WO2008098788A2 (en) * 2007-02-16 2008-08-21 Ktb Tumorforschungsgesellschaft Mbh Receptor and antigen targeted prodrug
WO2008098789A2 (en) * 2007-02-16 2008-08-21 Ktb Tumorforschungsgesellschaft Mbh Dual acting prodrugs
DK2907824T3 (en) 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
SI3088419T1 (sl) 2013-12-25 2019-01-31 Daiichi Sankyo Company Zdravilni konjugat anti trop2 protitelesa
DK3466976T3 (da) 2014-01-31 2021-12-13 Daiichi Sankyo Co Ltd Anti-her2-antistof-lægemiddelkonjugat
KR102351755B1 (ko) 2014-04-10 2022-01-14 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
WO2018110515A1 (ja) 2016-12-12 2018-06-21 第一三共株式会社 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
KR102537651B1 (ko) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
BR112020003466B1 (pt) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited Métodos de produção de composto, e, composto
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
JP2021524740A (ja) 2018-05-18 2021-09-16 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076550A2 (de) * 1999-06-10 2000-12-21 Ktb Tumorforschungsgesellschaft Mbh Träger-pharmaka-konjugate
WO2004078781A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungs Gmbh Protein-bindende doxorubicin-peptid-derivate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076550A2 (de) * 1999-06-10 2000-12-21 Ktb Tumorforschungsgesellschaft Mbh Träger-pharmaka-konjugate
WO2004078781A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungs Gmbh Protein-bindende doxorubicin-peptid-derivate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRATZ FELIX; MANSOUR AHMED; SOLTAU JENS; WARNECKE ANDRE; FICHTNER IDUNA; UNGER CLEMENS; DREVS JOACHIM: "Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen", ARCHIV DER PHARMAZIE, vol. 338, no. 10, October 2005 (2005-10-01), pages 462 - 472, XP002379896 *
WARNECKE A ET AL: "Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: Synthesis and antitumor efficacy", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 14, no. 2, April 2003 (2003-04-01), pages 377 - 387, XP002337008, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
WO2006092230A2 (de) 2006-09-08
DE102005009099A1 (de) 2006-08-31

Similar Documents

Publication Publication Date Title
WO2006092230A3 (de) Proteinbindende camptothecin-peptid-derivate und diese enthaltende arzneimittel
WO2007086001A3 (en) Novel pyridine derivatives
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
IL181301A0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
WO2007087431A3 (en) Sublingual fentanyl spray
IL206395A (en) N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them
WO2007146248A3 (en) Stable laquinimod preparations
WO2007008384A3 (en) Food articles with delivery devices and methods for the preparation thereof
WO2007079448A3 (en) Three component carbohydrate vaccine
WO2009117130A3 (en) Extended release forumulation containing a wax
WO2014096985A3 (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
WO2006111524A3 (en) Il-21 variants
WO2007093365A3 (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2006138048A3 (en) Formulations comprising fluphenazine or derivatives thereof
WO2008084698A1 (ja) タクロリムス徐放性医薬組成物
WO2007048027A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
WO2007003264A3 (de) Polyasparaginsäurederivate in polysiloxan-haltigen beschichtungsmitteln
EP1911761A4 (de) Wasserlösliche artemisininderivate, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und ihre verwendung
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
WO2009068708A8 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
WO2007133944A3 (en) Topical administration of acyclovir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06707186

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6707186

Country of ref document: EP